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Clinical follow-up of 122 Italian cystic fibrosis patients with
B. cepacia complex colonisationBSir,
We read with great interest the article by Courtney
regarding the clinical outcome of B. cepacia complex
infection in cystic fibrosis (CF) adults [1]. As the author
states, complex factors, regarding both the pathogen and the
patient, can influence the clinical outcome [1–6]. The
Courtney’s study is limited by the small number of patients
colonised by B. multivorans (3) and B. cenocepacia (16),
but emphasis is given to genomovar status and clonality in
conditioning survival, decreased pulmonary function and
nutritional status [1].
We are currently engaged in a multi-centre study in Italy
regarding clinical outcome and follow-up of Italian CF
patients with B. cepacia complex infection and we wish to
report our preliminary results here. The goal of our study
was to investigate the clinical evolution of a cohort of 122
Italian CF patients colonised by B. cepacia complex
through questionnaires sent to all Italian CF Centres. Age,
sex, concomitant respiratory colonisation, lung function
over time and mortality were assessed.
Fourteen out of 22 Italian CF Centres participated in the
study. Data on 122 patients (52 males, 70 females) were
collected. 26 patients (21.3%) were DF508 homozygote, 59
(48.4%) were compound heterozygotes (DF508/other), 13
(10.7%) were other/other, 4 (3.2%) were unk/unk and 20
(16.4%) were missing.
Courtney’s paper did not refer to concomitant colonisa-
tion in the selected study groups. Concomitant colonisation
by more than one pathogen occurs frequently in CF patients,
in those infected by B. cepacia as well as by other bacteria
such as P. aeruginosa [7].
In our cases, 40 (32.7%) patients were colonised by B.
cepacia complex alone, with 90 (77.5%) being chronically
colonised, 26 (22.5%) transiently and 4 missing. The mean
age of patients at colonisation was 16.1 years (F8.3, median
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colonisation was 9.8% (F22.2) in chronically colonised
and 4.93 (F9.6) in intermittently colonised. Three years
after B. cepacia complex colonisation, 14.4% of our chroni-
cally colonised patients died (missing data: 2), whereas no
deaths occurred in transiently colonised patients (Fisher test
p=0.03). Two out of three transplanted patients died.
Genomovar status was determined in 56/122 (45.9%) of
isolates. Thirty patients (53.6%) were infected with B.
cenocepacia, 6 (10.7%) with B. cepacia, 6 (10.7%) with B.
pyrrocinia, 5 (8.9%) with B. multivorans and 9 (16.1%) with
other genomovars. The clinical course of patients infected
with B. cenocepacia or B. multivorans is usually associated
with an increase in patient morbidity and mortality compared
to those infected with other genomovars, which is why we
compared mortality and FEV1 decline of patients infected by
different genomovars.
During the study period, 7/16 (43%) of the patients in
Courtney’s study, who were infected by a single B.
cenocepacia strain (IIIA, ET12), died [1]. In our study,
mortality 5 years after infection was 20.5% for patients
infected with B. cenocepacia or B. multivorans, versus 5.5%
for patients colonised by other genomovars.
Studies on B. cepacia complex clonality are ongoing in
Italy. Themean change in FEV1 (percent change compared to
baseline) 2 years after colonisation was 17.6% (F21.8) in
patients with B. cenocepacia or B. multivorans, and3.02%
(F19.2) in those colonised by other genomovars (t-test,
p=0.03).
On the basis of our experience, 3-year survival is worse in
patients with chronic B. cepacia complex colonisation
compared to those colonised transiently, and independently
of the clonality, the mean decrease in FEV1 is significantly
higher in patients with B. cenocepacia or B. multivorans than
in those with other genomovars.
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